Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2014 09:51 ET | Source: Exiqon A/S

Exiqon launches two new Research Use Only kits for PCR analysis of colon cancer samples.

Copenhagen, 2014-12-18 15:51 CET (GLOBE NEWSWIRE) -- Exiqon A/S today launched the miRSIGN™ miR-21 Oncogene assay, a Research Use Only kit for measuring miR-21 levels in relation to two...
December 18, 2014 09:51 ET | Source: Exiqon A/S

Exiqon lancerer to nye ‘Research Use Only’ kits til PCR analyse af kræftceller i vævsprøver fra tyktarmen.

København, 2014-12-18 15:51 CET (GLOBE NEWSWIRE) -- Exiqon A/S offentliggjorde i dag lanceringen af produktet ’miRSIGN™ miR-21 Oncogene’, et kit til forskningsbrug, der kan måle niveauet af...
December 03, 2014 08:36 ET | Source: Exiqon A/S

Exiqon tager licens til rettighederne for validerede biomarkører indenfor prostatakræft fra Aarhus Universitetshospital

København, 2014-12-03 14:36 CET (GLOBE NEWSWIRE) -- Exiqon A / S annoncerede i dag, at selskabet har taget licens til prostatakræft biomarkører, opdaget og valideret af Aarhus...
December 03, 2014 08:36 ET | Source: Exiqon A/S

Exiqon licenses validated biomarkers for prostate cancer from Aarhus University Hospital.

Copenhagen, 2014-12-03 14:36 CET (GLOBE NEWSWIRE) -- Exiqon A/S today announced that the company has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus...
October 27, 2014 11:06 ET | Source: Exiqon A/S

Exiqon A/S offentliggør finanskalender for 2015

Copenhagen, 2014-10-27 16:06 CET (GLOBE NEWSWIRE) -- Nedenstående viser forventede datoer for Exiqon A/S’ afholdelse af ordinær generalforsamling samt regnskabsrapportering i...
October 27, 2014 11:06 ET | Source: Exiqon A/S

Exiqon A/S announces financial calendar for 2015

Copenhagen, 2014-10-27 16:06 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced the expected dates for Exiqon A/S’ annual general meeting and financial reporting in...
October 27, 2014 10:38 ET | Source: Exiqon A/S

INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 SEPTEMBER 2014 (UNAUDITED)

Copenhagen, 2014-10-27 15:38 CET (GLOBE NEWSWIRE) -- Third quarter highlights include record services sales and record quarterly revenue. Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced...
September 12, 2014 10:07 ET | Source: Exiqon A/S

CORRECTION: Forbedret identifikation af højrisiko patienter med stadie II tyktarmskræft

Tidligere fremsendt børsmeddelelse på engelsk. Nu også på dansk. Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) annoncerede i dag offentliggørelsen af data fra et populationsstudie med 554...
September 12, 2014 04:19 ET | Source: Exiqon A/S

Redefining high risk patients with stage II colon cancer

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the publication of data from a population based study of 554 patients with stage II colon cancer, using the company’s proprietary miRCURY...
August 14, 2014 11:18 ET | Source: Exiqon A/S

INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 June 2014 (UNAUDITED)

Copenhagen, 2014-08-14 17:18 CEST (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the six months of 2014: In summary (DKK million) Q2...